Navigation Links
Verenium Corporation to Announce Fourth Quarter and Year-End 2010 Financial Results
Date:2/22/2011

projected in such forward-looking statements.  Factors that could cause or contribute to the differences include, but are not limited to, risks associated with Verenium's strategic focus, risks associated with Verenium's technologies, risks associated with Verenium's ability to obtain additional capital to support its planned operations and financial obligations, risks associated with Verenium's dependence on patents and proprietary rights, risks associated with Verenium's protection and enforcement of its patents and proprietary rights, the commercial prospects of the industries in which Verenium operates and sells products, Verenium's dependence on manufacturing and/or license agreements, and its ability to achieve milestones under existing and future collaboration agreements, the ability of Verenium and its partners to commercialize its technologies and products (including by obtaining any required regulatory approvals) using Verenium's technologies and timing for launching any commercial products and projects, the ability of Verenium and its collaborators to market and sell any products that it or they commercialize, the development or availability of competitive products or technologies, the future ability of Verenium to enter into and/or maintain collaboration and joint venture agreements and licenses, and risks and other uncertainties more fully described in Verenium's filings with the Securities and Exchange Commission, including, but not limited to, Verenium's annual report on Form 10-K for the year ended December 31, 2009 and any updates contained in its subsequently filed quarterly reports on Form 10-Q.  These forward-looking statements speak only as of the date hereof, and Verenium expressly disclaims any intent or obligation to update these forward-looking statements.

Contacts:

Kelly Lindenboom

Vice President, Corporate Communications

617-674-5335


SOURCE Verenium Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Verenium to Present at Jefferies 11th Global Clean Technology Conference
2. Verenium Announces Favorable Outcome of Capital Ventures International Lawsuit
3. Verenium to Present at Piper Jaffray Sixth Annual Clean Technology & Renewables Conference
4. Verenium Reports Financial Results for the Third Quarter 2010
5. Verenium to Present at Jefferies 10th Global Clean Technology Conference
6. Verenium and Alfa Laval Announce Extension of Purifine® PLC Enzyme Agreement
7. Verenium Announces Regulatory Approval for Purifine® PLC in China
8. Verenium Launches DELTAZYM® GA L-E5 Enzyme for Fuel Ethanol Production
9. Verenium Appoints Kevin Bracken Vice President of Manufacturing
10. Verenium Announces Proposed Public Offering of Common Stock
11. Verenium 1:12 Reverse Stock Split Takes Effect
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... across the globe, ISN improves the efficiency and effectiveness of contractor management systems. ISN,s ... reliable contractors in over 80 countries. ... ... Over 60,000 Worldwide Customers In More Than 80 Countries ... Headquartered in Dallas, TX , ISN has additional offices in Calgary ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... and designed for continuous operation up to 1500 bar. The sanitary design gauge ... and preventing toxic contamination. , The Pony™ NS2006L homogenizer is an ideal solution ...
(Date:7/29/2015)... / Japan (Q2 2015: +14% CER / ... on high-single-digit growth in China , as well as solid ... . Europe / Middle East ... sales) showed gains in Germany , Turkey ... +4% CER / 49% of sales) grew 11%, excluding U.S. HPV sales, on ...
(Date:7/29/2015)... , July 29, 2015 ... has announced the addition of the "Global ... their offering. The Global Biosimilars Market, ... of the rapidly growing biosimilars market. With the ... striving to minimize costs, biosimilars are being viewed ...
Breaking Biology Technology:ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2QIAGEN Reports Results for Second Quarter and First Half of 2015 2QIAGEN Reports Results for Second Quarter and First Half of 2015 3QIAGEN Reports Results for Second Quarter and First Half of 2015 4QIAGEN Reports Results for Second Quarter and First Half of 2015 5QIAGEN Reports Results for Second Quarter and First Half of 2015 6QIAGEN Reports Results for Second Quarter and First Half of 2015 7QIAGEN Reports Results for Second Quarter and First Half of 2015 8QIAGEN Reports Results for Second Quarter and First Half of 2015 9QIAGEN Reports Results for Second Quarter and First Half of 2015 10Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 3
... June 11 MedNet Solutions, a global life sciences ... will unveil a variety of exciting new and enhanced ... Annual Meeting, June 22-24, 2009, in San Diego, CA. ... its market-leading electronic data capture/eClinical tool set to improve ...
... ... how Earned Value Management can improve control over clinical development costs, payments, and accruals ... , ... (PRWEB) June 11, 2009 -- ClearTrial ( www.cleartrial.com ), a leading provider of clinical ...
... (Nasdaq: MDVN ) today ... CONNECTION study, a six-month, confirmatory, pivotal Phase 3 trial ... Alzheimer,s disease. , , The international, double-blind, ... the enrollment target of 525 patients. More than 40 ...
Cached Biology Technology:MedNet Solutions to Introduce New EDC/eClinical Technologies at the 2009 Drug Information Association Annual Meeting 2ClearTrial Industry Expert to Lead Session at DIA Annual Meeting on Improving Accrual and Contract Management in Clinical Trials 2Medivation Completes Enrollment in Confirmatory, Pivotal Phase 3 'CONNECTION' Trial of Dimebon in Patients With Alzheimer's Disease 2Medivation Completes Enrollment in Confirmatory, Pivotal Phase 3 'CONNECTION' Trial of Dimebon in Patients With Alzheimer's Disease 3Medivation Completes Enrollment in Confirmatory, Pivotal Phase 3 'CONNECTION' Trial of Dimebon in Patients With Alzheimer's Disease 4
(Date:7/21/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ... focused on the growing mobile commerce market and ... it has filed provisional patent 62/192218 for ... This invention highlights next generation payment technology ... but also the user using unique personal identifiers ...
(Date:7/13/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ... today announced sampling of ClearPad ® 4300, ... (TDDI) product targeting smartphones and tablets. This new ... , best-in-class touch controller IP and systems ... in the company,s Japan Design Center. TDDI enables ...
(Date:7/9/2015)... 2015 Research and ... the "Biometrics for Banking; Market & Technology ... to their offering. The adoption for ... growth and the forecast is that by 2020 ... companies involved in delivering biometric systems to the ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3
... vibrant insects, with colorations sometimes designed to deflect predators. ... defenses may be driven by enemies one-tenth their size. ... researchers have believed large predators like birds mainly influenced ... behavioral study to directly test the defense mechanism of ...
... be it heat or electricity, has to be used right ... its transportation can be rather complicated. Creating solar cells capable ... that is to say fuel, is therefore the future challenge ... are working on a catalyst that imitates and improves what ...
... amino acids in order to conduct electricity, according to a ... open-access journal of the American Society for Microbiology, on Tuesday, ... sulfurreducens uses these nanowires, called pili, to transport electrons ... of these wires can also be harnessed by humans for ...
Cached Biology News:UF study shows spiders, not birds, may drive evolution of some butterflies 2UF study shows spiders, not birds, may drive evolution of some butterflies 3Catalysts that produce 'green' fuel 2Biological wires carry electricity thanks to special amino acids 2
... number is a new product ... Cornings product number. If showing ... under the old Sigma-Aldrich number ... for assistance. Material: cap ...
Formula variant: With macro- and micronutrients. Physical Form: powder Suitab tst: plant cell culture tested...
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. ...
Four siRNAs targeting your gene of interest, providing gene silencing with 100% satisfaction guaranteed High knockdown potency , High specificity for minimal off-target effects , Flexible siR...
Biology Products: